Click for best price
Postpemic Era Duchenne Muscular Dystrophy Drugs Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
(Post-pandemic Era)-Global Duchenne Muscular Dystrophy Drugs Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Duchenne Muscular Dystrophy Drugs industry at home and abroad, estimate the overall market scale of the Duchenne Muscular Dystrophy Drugs industry and the market share of major countries, Duchenne Muscular Dystrophy Drugs industry, and study and judge the downstream market demand of Duchenne Muscular Dystrophy Drugs through systematic research, Analyze the competition pattern of Duchenne Muscular Dystrophy Drugs, so as to help solve the pain points of various stakeholders in Duchenne Muscular Dystrophy Drugs industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Duchenne Muscular Dystrophy Drugs Market by Research Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Duchenne Muscular Dystrophy Drugs Market?
Biogen
Roche
Daiichi Sankyo
Pfizer
Cumberland Pharmaceuticals
Santhera Pharmaceuticals
Taiho Pharmaceutical
Teijin Pharma
Akashi Therapeutics
Sarepta Therapeutics
BioMarin
Fibrogen Inc
Nobelpharma Co. Ltd
Eloxx Pharmaceuticals
Major Type of Duchenne Muscular Dystrophy Drugs Covered in Research report:
Molecular-based Therapies
Steroid Therapy
Other
Application Segments Covered in Research Market
Hospitals
Clinics
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Duchenne Muscular Dystrophy Drugs Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
117 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Duchenne Muscular Dystrophy Drugs Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Duchenne Muscular Dystrophy Drugs Market by Value
2.2.1 Global Duchenne Muscular Dystrophy Drugs Revenue by Type
2.2.2 Global Duchenne Muscular Dystrophy Drugs Market by Value (%)
2.3 Global Duchenne Muscular Dystrophy Drugs Market by Production
2.3.1 Global Duchenne Muscular Dystrophy Drugs Production by Type
2.3.2 Global Duchenne Muscular Dystrophy Drugs Market by Production (%)
3. The Major Driver of Duchenne Muscular Dystrophy Drugs Industry
3.1 Historical & Forecast Global Duchenne Muscular Dystrophy Drugs Demand
3.2 Largest Application for Duchenne Muscular Dystrophy Drugs (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Duchenne Muscular Dystrophy Drugs Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Duchenne Muscular Dystrophy Drugs Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Demand Breakdown by Type
5.3 Current and Estimated Demand Breakdown by Application
5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Demand Breakdown by Type
6.3 Current and Estimated Demand Breakdown by Application
6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Demand Breakdown by Type
7.3 Current and Estimated Demand Breakdown by Application
7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Demand Breakdown by Type
8.3 Current and Estimated Demand Breakdown by Application
8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Demand Breakdown by Type
9.3 Current and Estimated Demand Breakdown by Application
9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Demand Breakdown by Type
10.3 Current and Estimated Demand Breakdown by Application
10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Demand Breakdown by Type
11.3 Current and Estimated Demand Breakdown by Application
11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. Global Duchenne Muscular Dystrophy Drugs Average Price Trend
12.1 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in US (2018-2022)
12.2 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in Europe (2018-2022)
12.3 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in China (2018-2022)
12.4 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in Japan (2018-2022)
12.5 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in India (2018-2022)
12.6 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in Korea (2018-2022)
12.7 Market Price for Each Type of Duchenne Muscular Dystrophy Drugs in Southeast Asia (2018-2022)
13. Industrial Chain (Impact of COVID-19)
13.1 Duchenne Muscular Dystrophy Drugs Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Duchenne Muscular Dystrophy Drugs
14. Duchenne Muscular Dystrophy Drugs Competitive Landscape
14.1 Biogen
14.1.1 Biogen Company Profiles
14.1.2 Biogen Product Introduction
14.1.3 Biogen Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Roche
14.2.1 Roche Company Profiles
14.2.2 Roche Product Introduction
14.2.3 Roche Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Daiichi Sankyo
14.3.1 Daiichi Sankyo Company Profiles
14.3.2 Daiichi Sankyo Product Introduction
14.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Pfizer
14.4.1 Pfizer Company Profiles
14.4.2 Pfizer Product Introduction
14.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 Cumberland Pharmaceuticals
14.5.1 Cumberland Pharmaceuticals Company Profiles
14.5.2 Cumberland Pharmaceuticals Product Introduction
14.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 Santhera Pharmaceuticals
14.6.1 Santhera Pharmaceuticals Company Profiles
14.6.2 Santhera Pharmaceuticals Product Introduction
14.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 Taiho Pharmaceutical
14.7.1 Taiho Pharmaceutical Company Profiles
14.7.2 Taiho Pharmaceutical Product Introduction
14.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 Teijin Pharma
14.8.1 Teijin Pharma Company Profiles
14.8.2 Teijin Pharma Product Introduction
14.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 Akashi Therapeutics
14.9.1 Akashi Therapeutics Company Profiles
14.9.2 Akashi Therapeutics Product Introduction
14.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Sarepta Therapeutics
14.10.1 Sarepta Therapeutics Company Profiles
14.10.2 Sarepta Therapeutics Product Introduction
14.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Sales, Revenue (2018-2022)
14.10.4 Strategic initiatives
14.11 BioMarin
14.12 Fibrogen Inc
14.13 Nobelpharma Co. Ltd
14.14 Eloxx Pharmaceuticals
15. Conclusion
16. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Demand by Application of Duchenne Muscular Dystrophy Drugs Industry (Volume)
Figure 2. Duchenne Muscular Dystrophy Drugs Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2022
Figure 5. US Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Duchenne Muscular Dystrophy Drugs Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Duchenne Muscular Dystrophy Drugs Revenue, by Type (Million USD) (2018-2028)
Table 4. Duchenne Muscular Dystrophy Drugs Production, by Type (K Unit) (2018-2028)
Table 5. Duchenne Muscular Dystrophy Drugs Demand (K Unit) by Application (2018-2028)
Table 6. Duchenne Muscular Dystrophy Drugs Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Duchenne Muscular Dystrophy Drugs Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Duchenne Muscular Dystrophy Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Duchenne Muscular Dystrophy Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Duchenne Muscular Dystrophy Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Duchenne Muscular Dystrophy Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Duchenne Muscular Dystrophy Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Duchenne Muscular Dystrophy Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Duchenne Muscular Dystrophy Drugs Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Duchenne Muscular Dystrophy Drugs in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Biogen Profiles
Table 61. Biogen Duchenne Muscular Dystrophy Drugs Product Introduction
Table 62. Biogen Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Biogen Strategic initiatives
Table 64. Roche Profiles
Table 65. Roche Duchenne Muscular Dystrophy Drugs Product Introduction
Table 66. Roche Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Roche Strategic initiatives
Table 68. Daiichi Sankyo Profiles
Table 69. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product Introduction
Table 70. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Daiichi Sankyo Strategic initiatives
Table 72. Pfizer Profiles
Table 73. Pfizer Duchenne Muscular Dystrophy Drugs Product Introduction
Table 74. Pfizer Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Pfizer Strategic initiatives
Table 76. Cumberland Pharmaceuticals Profiles
Table 77. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Introduction
Table 78. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Cumberland Pharmaceuticals Strategic initiatives
Table 80. Santhera Pharmaceuticals Profiles
Table 81. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Introduction
Table 82. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Santhera Pharmaceuticals Strategic initiatives
Table 84. Taiho Pharmaceutical Profiles
Table 85. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product Introduction
Table 86. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Taiho Pharmaceutical Strategic initiatives
Table 88. Teijin Pharma Profiles
Table 89. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product Introduction
Table 90. Teijin Pharma Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Teijin Pharma Strategic initiatives
Table 92. Akashi Therapeutics Profiles
Table 93. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product Introduction
Table 94. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. Akashi Therapeutics Strategic initiatives
Table 97. Sarepta Therapeutics Profiles
Table 98. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product Introduction
Table 99. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Sarepta Therapeutics Strategic initiatives
Table 101. BioMarin Profiles
Table 102. BioMarin Duchenne Muscular Dystrophy Drugs Product Introduction
Table 103. BioMarin Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 104. BioMarin Strategic initiatives
Table 105. Fibrogen Inc Profiles
Table 106. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product Introduction
Table 107. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 108. Fibrogen Inc Strategic initiatives
Table 109. Nobelpharma Co. Ltd Profiles
Table 110. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product Introduction
Table 111. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 112. Nobelpharma Co. Ltd Strategic initiatives
Table 113. Eloxx Pharmaceuticals Profiles
Table 114. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Introduction
Table 115. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Sales (Unit), Revenue (Million USD) (2018-2022)
Table 116. Eloxx Pharmaceuticals Strategic initiatives
